目的 調查住院患者接受達格列凈治療的情況，了解該藥的應用現狀和不良反應并分析其危險因素，為規(guī)范其臨床合理應用提供依據。方法 檢索PubMed、中國知網、萬方和維普數據庫，匯總國內外達格列凈相關指南、文獻和專家共識，形成達格列凈臨床應用的合理性評價標準?；仡櫺哉{查廣州醫(yī)科大學附屬第二醫(yī)院2021年3月1日—2022年2月28日住院患者使用達格列凈的情況，按照已制定的評價標準進行合理性和安全性分析，并提出合理化用藥建議。結果 共有201例患者應用了達格列凈，其中有效病例198例，不合理用藥病例共27例，不合理使用率為13.64%，以用藥時機不適宜、禁忌證用藥和特殊人群用藥不合理為主要原因。不良反應共6例，發(fā)生率為3.03%，以泌尿系感染、糖尿病酮癥和糖尿病酮癥酸中毒等不良反應為主。結論 達格列凈降低血糖和改善心力衰竭預后的作用越來越受到臨床醫(yī)生重視，臨床用藥期間應多關注患者的血β-羥基丁酸和肝腎功能指標，關注達格列凈的用藥時機、特殊人群用藥和不良反應等方面。針對其不合理應用情況和不良反應，臨床藥師應結合達格列凈新修訂的說明書、臨床指南和專家共識等最新信息，制定合理性評價標準和用藥建議，做到實時點評，進一步促進鈉–葡萄糖共轉運蛋白2抑制劑（SGLT2i）的合理使用。

Objective To explore the treatment of dapagliflozin in hospitalized patients to understand the status quo and its adverse reactions and analyze its risk factors, so as to provide a basis for regulating its rational clinical application. Methods PubMed, CNKI, Wanfang, and VIP databases were searched, and the relevant guidelines, literatures and expert consensus of dapagliflozin at home and abroad were summarized to form the rationality evaluation standard of dapagliflozin in clinical application. The use of dapagliflozin in inpatients in the Second Affiliated Hospital of Guangzhou Medical University from March 1, 2021 to February 28, 2022 was retrospectively investigated. The rationality and safety of dapagliflozin were analyzed according to the established evaluation criteria, and rational medication suggestions were put forward. Results A total of 201 patients were treated with dapagliflozin, including 198 effective cases, There were 27 cases of irrational drug use, and the rate of irrational drug use was 13.64%. The main reasons were inappropriate medication timing, contraindications, and irrational drug use in special population. There were 6 cases of adverse reactions, the incidence of which was 3.03%. The main adverse reactions were urinary tract infection, diabetic ketosis, and diabetic ketoacidosis. Conclusion The role of dapagliflozin in reducing blood glucose and improving the prognosis of heart failure has attracted more and more attention from clinicians. During clinical medication, more attention should be paid to the blood β-hydroxybutyric acid and liver and kidney function indexes of patients, the timing of dapagliflozin administration, special population medication, and adverse reactions. In view of the irrational use and adverse reactions of dapagliflozin, clinical pharmacists should formulate rationality evaluation criteria and medication recommendations based on the latest information such as the newly revised instructions, clinical guidelines and expert consensus, so as to make real-time comments and further promote the rational use of sodia-glucose cotransporter 2 inhibitor (SGLT2i).

R977